Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Toward a Single-Dose Cure for Buruli Ulcer.

Literature DB >> 32631818

Toward a Single-Dose Cure for Buruli Ulcer.

Sangeeta S Thomas^1,2, Nitin Pal Kalia^2,3, Marie-Thérèse Ruf^4,5, Gerd Pluschke^4,5, Kevin Pethe^6,7.

Abstract

A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.

Entities: Disease Species

Keywords: Mycobacterium ulcerans; Q203; Telacebec; bedaquiline; bioenergetics; cytochrome bcc-aa3; oxidative phosphorylation; terminal oxidase; tuberculosis

Mesh：

Year: 2020 PMID： 32631818 PMCID： PMC7449209 DOI： 10.1128/AAC.00727-20

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

14 in total

1. The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in the mouse and the developing chick embryo.

Authors: F FENNER
Journal: Am Rev Tuberc Date: 1956-05

2. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors: Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal: Science Date: 2004-12-09 Impact factor: 47.728

3. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

Authors: Baohong Ji; Sébastien Lefrançois; Jerome Robert; Aurélie Chauffour; Chantal Truffot; Vincent Jarlier
Journal: Antimicrob Agents Chemother Date: 2006-06 Impact factor: 5.191

4. Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer.

Authors: Timothy P Stinear; Torsten Seemann; Sacha Pidot; Wafa Frigui; Gilles Reysset; Thierry Garnier; Guillaume Meurice; David Simon; Christiane Bouchier; Laurence Ma; Magali Tichit; Jessica L Porter; Janine Ryan; Paul D R Johnson; John K Davies; Grant A Jenkin; Pamela L C Small; Louis M Jones; Fredj Tekaia; Françoise Laval; Mamadou Daffé; Julian Parkhill; Stewart T Cole
Journal: Genome Res Date: 2007-01-08 Impact factor: 9.043

Review 5. Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors: Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal: Clin Microbiol Rev Date: 2017-12-13 Impact factor: 26.132

6. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

Authors: Kevin Pethe; Pablo Bifani; Jichan Jang; Sunhee Kang; Seijin Park; Sujin Ahn; Jan Jiricek; Juyoung Jung; Hee Kyoung Jeon; Jonathan Cechetto; Thierry Christophe; Honggun Lee; Marie Kempf; Mary Jackson; Anne J Lenaerts; Ha Pham; Victoria Jones; Min Jung Seo; Young Mi Kim; Mooyoung Seo; Jeong Jea Seo; Dongsik Park; Yoonae Ko; Inhee Choi; Ryangyeo Kim; Se Yeon Kim; SeungBin Lim; Seung-Ae Yim; Jiyoun Nam; Hwankyu Kang; Haejin Kwon; Chun-Taek Oh; Yoojin Cho; Yunhee Jang; Junghwan Kim; Adeline Chua; Bee Huat Tan; Mahesh B Nanjundappa; Srinivasa P S Rao; Whitney S Barnes; René Wintjens; John R Walker; Sylvie Alonso; Saeyeon Lee; Jungjun Kim; Soohyun Oh; Taegwon Oh; Ulf Nehrbass; Sung-Jun Han; Zaesung No; Jinhwa Lee; Priscille Brodin; Sang-Nae Cho; Kiyean Nam; Jaeseung Kim
Journal: Nat Med Date: 2013-08-04 Impact factor: 53.440

7. Targeting the Mycobacterium ulcerans cytochrome bc₁:aa₃ for the treatment of Buruli ulcer.

Authors: Nicole Scherr; Raphael Bieri; Sangeeta S Thomas; Aurélie Chauffour; Nitin Pal Kalia; Paul Schneide; Marie-Thérèse Ruf; Araceli Lamelas; Malathy S S Manimekalai; Gerhard Grüber; Norihisa Ishii; Koichi Suzuki; Marcel Tanner; Garrett C Moraski; Marvin J Miller; Matthias Witschel; Vincent Jarlier; Gerd Pluschke; Kevin Pethe
Journal: Nat Commun Date: 2018-12-18 Impact factor: 14.919

8. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.

Authors: Aurélie Chauffour; Jérôme Robert; Nicolas Veziris; Alexandra Aubry; Vincent Jarlier
Journal: PLoS Negl Trop Dis Date: 2016-10-18

9. Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia.

Authors: Alex Y C Tai; Eugene Athan; N Deborah Friedman; Andrew Hughes; Aaron Walton; Daniel P O'Brien
Journal: Emerg Infect Dis Date: 2018-01-17 Impact factor: 6.883

10. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.

Authors: Richard O Phillips; Jérôme Robert; Kabiru Mohamed Abass; William Thompson; Fred Stephen Sarfo; Tuah Wilson; Godfred Sarpong; Thierry Gateau; Annick Chauty; Raymond Omollo; Michael Ochieng Otieno; Thaddaeus W Egondi; Edwin O Ampadu; Didier Agossadou; Estelle Marion; Line Ganlonon; Mark Wansbrough-Jones; Jacques Grosset; John M Macdonald; Terry Treadwell; Paul Saunderson; Albert Paintsil; Linda Lehman; Michael Frimpong; Nanaa Francisca Sarpong; Raoul Saizonou; Alexandre Tiendrebeogo; Sally-Ann Ohene; Ymkje Stienstra; Kingsley B Asiedu; Tjip S van der Werf
Journal: Lancet Date: 2020-03-12 Impact factor: 79.321

5 in total

1. Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.

Authors: Oliver Komm; Deepak V Almeida; Paul J Converse; Till F Omansen; Eric L Nuermberger
Journal: Antimicrob Agents Chemother Date: 2021-08-30 Impact factor: 5.191

Review 5. Mycobacterial skin infection.

Authors: Giulia Gardini; Natalia Gregori; Alberto Matteelli; Francesco Castelli
Journal: Curr Opin Infect Dis Date: 2022-04-01 Impact factor: 4.915